Business Context and Reporting Period
This Form 8-K filing by Ocular Therapeutix, Inc. (a Delaware corporation) was submitted on November 5, 2015. The report details a corporate governance event regarding the expansion of the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to director compensation: Mr. O'Shea received an option to purchase 11,363 shares of common stock at an exercise price of $10.75 per share.
Material Changes
- Board Expansion: The Board of Directors increased its size from seven to eight members.
- New Appointment: W. James O'Shea was elected as a new director, effective November 5, 2015.
- Term: Mr. O'Shea was designated as a Class I director, serving until the 2018 annual meeting of stockholders.
Management Commentary, Risks, and Contingencies
Management confirmed there are no arrangements or understandings between Mr. O'Shea and any other person regarding his election. He will be compensated in the same manner as other non-employee directors. A standard Indemnification Agreement was executed, which may require the Company to indemnify Mr. O'Shea for expenses, including attorneys' fees, judgments, fines, and settlement amounts incurred in actions arising from his service as a director.
Investor Verification Checklist
- Verify the total number of directors on the Board is now eight.
- Confirm the terms of the stock option granted (11,363 shares at $10.75 exercise price).
- Review the Company's proxy statement filed on April 24, 2015, for details on standard director compensation.
- Note that this filing contains no updates on the Company's clinical pipeline or financial status.